**Author details**

Manuel Torres1,2\*, Xavier Busquets1 and Pablo V. Escribá1\*

\*Address all correspondence to: manuel.torres.phd@gmail.com and Pablo.escriba@uib.es

1 Laboratory of Molecular Cell Biomedicine, University of the Balearic Islands, Palma de Mallorca, Spain

2 Lipopharma Therapeutics S.L., Palma de Mallorca, Spain

## **References**


[4] Harman D. Alzheimer's disease pathogenesis: role of aging. Ann N Y Acad Sci. 2006;1067:454–60.

**Acknowledgements**

154 Update on Dementia

tividad.

Islands.

**Conflict of interest**

**Author details**

Mallorca, Spain

**References**

Manuel Torres1,2\*, Xavier Busquets1

2 Lipopharma Therapeutics S.L., Palma de Mallorca, Spain

Ann N Y Acad Sci. 2000;920:158–64.

models. Annu Rev Neurosci. 1998;21:479–505.

Springer is the original publisher of images shown in **Figure 2**. These pictures were reproduced with permission from Springer and were adapted from [12] (please see full credits in the reference list). The authors wish to thank the original publisher as well as the original authors (Dr. Isidre Ferrer and co-workers) for allowing reproduction of these images in the present work. Information concerning clinical trials of several drugs has been obtained from the website http://www.alzforum.org/therapeutics. This work was supported in part by grants from the Spanish Ministerio de Economía y Competitividad (BIO2010-21132, IPT-010000-2010-16, BIO2013-49006-C2-1-R, RTC-2015-3542, RTC-2015-4094 to PVE and XB), with co-financing from EU FEDER funds, by grants to Research Groups of Excellence from the Govern de les Illes Balears, Spain (PVE), and by the Marathon Foundation (Spain). MT was a recipient of a Torres-Quevedo contract from the Spanish Ministerio de Economía y Competi‐

MT was supported by a Torres-Quevedo Research Contract granted to Lipopharma Thera‐ peutics, S.L., from the Ministerio de Economía y Competitividad (Spanish Government). Lipopharma Therapeutics, S.L., is a spin-off company from the University of the Balearic

and Pablo V. Escribá1\*

\*Address all correspondence to: manuel.torres.phd@gmail.com and Pablo.escriba@uib.es

1 Laboratory of Molecular Cell Biomedicine, University of the Balearic Islands, Palma de

[1] Castellani RJ, Rolston RK, Smith MA. Alzheimer disease. Dis Mon. 2010;56(9):484–546.

[2] Annaert W, Cupers P, Saftig P, De Strooper B. Presenilin function in APP processing.

[3] Price DL, Sisodia SS. Mutant genes in familial Alzheimer's disease and transgenic


[33] Thimiri Govinda Raj DB, Ghesquière B, Tharkeshwar AK, Coen K, Derua R, Vander‐ schaeghe D, et al. A novel strategy for the comprehensive analysis of the biomolecular composition of isolated plasma membranes. Mol Syst Biol. 2011;7:541.

[20] Yu WH, Cuervo AM, Kumar A, Peterhoff CM, Schmidt SD, Lee J-H, et al. Macroau‐ tophagy – a novel Beta-amyloid peptide-generating pathway activated in Alzheimer's

[21] Zhang X-M, Cai Y, Xiong K, Cai H, Luo X-G, Feng J-C, et al. Beta-secretase-1 elevation in transgenic mouse models of Alzheimer's disease is associated with synaptic/axonal pathology and amyloidogenesis: implications for neuritic plaque development. Eur J

[22] Doehner J, Genoud C, Imhof C, Krstic D, Knuesel I. Extrusion of misfolded and aggregated proteins--a protective strategy of aging neurons? Eur J Neurosci.

[23] Sanchez-Varo R, Trujillo-Estrada L, Sanchez-Mejias E, Torres M, Baglietto-Vargas D, Moreno-Gonzalez I, et al. Abnormal accumulation of autophagic vesicles correlates with axonal and synaptic pathology in young Alzheimer's mice hippocampus. Acta

[24] Mattson MP, Magnus T. Ageing and neuronal vulnerability. Nat Rev Neurosci.

[25] Krstic D, Knuesel I. Deciphering the mechanism underlying late-onset Alzheimer

[26] Knowles JK, Rajadas J, Nguyen T-VV, Yang T, LeMieux MC, Vander Griend L, et al. The p75 neurotrophin receptor promotes amyloid-beta(1–42)-induced neuritic dystro‐

[27] Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, et al. Neuroinflammation in Alzheimer's disease. Lancet Neurol. 2015;14(4):388–405.

[28] Jimenez S, Baglietto-Vargas D, Caballero C, Moreno-Gonzalez I, Torres M, Sanchez-Varo R, et al. Inflammatory response in the hippocampus of PS1M146L/APP751SL mouse model of Alzheimer's disease: age-dependent switch in the microglial pheno‐

[29] Wakabayashi T, De Strooper B. Presenilins: members of the gamma-secretase quartets,

[30] De Strooper B, Annaert W. Novel research horizons for presenilins and γ-secretases in

[31] Chávez-Gutiérrez L, Bammens L, Benilova I, Vandersteen A, Benurwar M, Borgers M, et al. The mechanism of γ-Secretase dysfunction in familial Alzheimer disease. EMBO

[32] Bentahir M, Nyabi O, Verhamme J, Tolia A, Horré K, Wiltfang J, et al. Presenilin clinical mutations can affect gamma-secretase activity by different mechanisms. J Neurochem.

disease. J Cell Biol. 2005;171(1):87–98.

Neurosci. 2009;30(12):2271–83.

Neuropathol. 2012;123(1):53–70.

disease. Nat Rev Neurol. 2013;9(1):25–34.

phy *in vitro* and *in vivo*. J Neurosci. 2009;29(34):10627–37.

type from alternative to classic. J Neurosci. 2008;28(45):11650–61.

but part-time soloists too. Physiology (Bethesda). 2008;23:194–204.

cell biology and disease. Annu Rev Cell Dev Biol. 2010;26:235–60.

2012;35(12):1938–50.

156 Update on Dementia

2006;7(4):278–94.

J. 2012;31(10):2261–74.

2006;96(3):732–42.


[59] Bhat NR, Thirumangalakudi L. Increased tau phosphorylation and impaired brain insulin/IGF signaling in mice fed a high fat/high cholesterol diet. J Alzheimers Dis. 2013;36(4):781–9.

[47] Chan RB, Oliveira TG, Cortes EP, Honig LS, Duff KE, Small SA, et al. Comparative lipidomic analysis of mouse and human brain with Alzheimer disease. J Biol Chem.

Involvement of oxidative stress-induced abnormalities in ceramide and cholester‐ ol metabolism in brain aging and Alzheimer's disease. Proc Natl Acad Sci U S

[49] Ledesma MD, Abad-Rodriguez J, Galvan C, Biondi E, Navarro P, Delacourte A, et al. Raft disorganization leads to reduced plasmin activity in Alzheimer's disease brains.

[50] Lai AY, McLaurin J. Mechanisms of amyloid-Beta peptide uptake by neurons: the role of lipid rafts and lipid raft-associated proteins. Int J Alzheimers Dis. 2010;2011:548380.

[51] Kalvodova L, Kahya N, Schwille P, Ehehalt R, Verkade P, Drechsel D, et al. Lipids as modulators of proteolytic activity of BACE: involvement of cholesterol, glycosphingo‐

[52] Holmes O, Paturi S, Ye W, Wolfe MS, Selkoe DJ. Effects of membrane lipids on the activity and processivity of purified γ-secretase. Biochemistry. 2012;51(17):3565–75.

[53] Askarova S, Yang X, Lee JCM. Impacts of membrane biophysics in Alzheimer's disease: from amyloid precursor protein processing to Aβ peptide-induced membrane changes.

[54] Runz H, Rietdorf J, Tomic I, de Bernard M, Beyreuther K, Pepperkok R, et al. Inhibition of intracellular cholesterol transport alters presenilin localization and amyloid precur‐

[55] Tamboli IY, Hampel H, Tien NT, Tolksdorf K, Breiden B, Mathews PM, et al. Sphin‐ golipid storage affects autophagic metabolism of the amyloid precursor protein and

[56] Lazarov O, Morfini GA, Pigino G, Gadadhar A, Chen X, Robinson J, et al. Impairments in fast axonal transport and motor neuron deficits in transgenic mice expressing familial Alzheimer's disease-linked mutant presenilin 1. J Neurosci. 2007;27(26):7011–20.

[57] Boland B, Kumar A, Lee S, Platt FM, Wegiel J, Yu WH, et al. Autophagy induction and autophagosome clearance in neurons: relationship to autophagic pathology in Alz‐

[58] Torres M, Jiménez S, Sánchez-Varo R, Navarro V, Trujillo-Estrada L, Sánchez-Mejias E, et al. Defective lysosomal proteolysis and axonal transport are early pathogenic events that worsen with age leading to increased APP metabolism and synaptic Abeta in transgenic APP/PS1 hippocampus. Mol Neurodegener.

sor protein processing in neuronal cells. J Neurosci. 2002;22(5):1679–89.

promotes Abeta generation. J Neurosci. 2011;31(5):1837–49.

heimer's disease. J Neurosci. 2008;28(27):6926–37.

2012;7:59. Epub 2012/11/24.

lipids, and anionic phospholipids *in vitro*. J Biol Chem. 2005;280(44):36815–23.

[48] Cutler RG, Kelly J, Storie K, Pedersen WA, Tammara A, Hatanpaa K, et al.

2012;287(4):2678–88.

158 Update on Dementia

A. 2004;101(7):2070–5.

EMBO Rep. 2003;4(12):1190–6.

Int J Alzheimer's Dis. 2011;2011:134971.


[84] Ritter A, Cummings J. Fluid biomarkers in clinical trials of Alzheimer's disease therapeutics. Front Neurol. 2015;6:186.

[72] Martín V, Fabelo N, Santpere G, Puig B, Marín R, Ferrer I, et al. Lipid alterations in lipid rafts from Alzheimer's disease human brain cortex. J Alzheimers Dis. 2010;19(2):489–

[73] Shaikh SR. Biophysical and biochemical mechanisms by which dietary N-3 polyunsa‐ turated fatty acids from fish oil disrupt membrane lipid rafts. J Nutr Biochem.

[74] Serhan CN. Pro-resolving lipid mediators are leads for resolution physiology. Nature.

[75] Stark DT, Bazan NG. Neuroprotectin D1 induces neuronal survival and downregula‐ tion of amyloidogenic processing in Alzheimer's disease cellular models. Mol Neuro‐

[76] Zhao Y, Calon F, Julien C, Winkler JW, Petasis NA, Lukiw WJ, et al. Docosahexaenoic acid-derived neuroprotectin D1 induces neuronal survival via secretase- and PPARγmediated mechanisms in Alzheimer's disease models. PLoS One. 2011;6(1):e15816.

[77] Simopoulos AP. Evolutionary aspects of diet, the omega-6/omega-3 ratio and genetic variation: nutritional implications for chronic diseases. Biomed Pharmacother.

[78] Wu S, Ding Y, Wu F, Li R, Hou J, Mao P. Omega-3 fatty acids intake and risks of dementia and Alzheimer's disease: a meta-analysis. Neurosci Biobehav Rev. 2015;48:1–

[79] Barberger-Gateau P, Raffaitin C, Letenneur L, Berr C, Tzourio C, Dartigues JF, et al. Dietary patterns and risk of dementia: the Three-City cohort study. Neurology.

[80] Quinn JF, Raman R, Thomas RG, Yurko-Mauro K, Nelson EB, Van Dyck C, et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a

[81] Hong S, Tjonahen E, Morgan EL, Lu Y, Serhan CN, Rowley AF. Rainbow trout (Oncorhynchus mykiss) brain cells biosynthesize novel docosahexaenoic acid-derived resolvins and protectins—mediator lipidomic analysis. Prostaglandins Other Lipid

[82] Afshordel S, Hagl S, Werner D, Röhner N, Kögel D, Bazan NG, et al. Omega-3 poly‐ unsaturated fatty acids improve mitochondrial dysfunction in brain aging—impact of Bcl-2 and NPD-1 like metabolites. Prostaglandins Leukot Essent Fatty Acids.

[83] Gómez-Isla T, Price JL, McKeel DW, Morris JC, Growdon JH, Hyman BT. Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J

502.

160 Update on Dementia

2012;23(2):101–5.

2014;510(7503):92–101.

biol. 2011;43(2):131–8.

2006;60(9):502–7.

2007;69(20):1921–30.

Mediat. 2005;78(1–4):107–16.

Neurosci. 1996;16(14):4491–500.

2015;92:23–31.

randomized trial. JAMA. 2010;304(17):1903–11.

9.


[110] Numata K, Kaplan DL. Mechanisms of enzymatic degradation of amyloid Beta microfibrils generating nanofilaments and nanospheres related to cytotoxicity. Biochemistry. 2010;49(15):3254–60.

[98] Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt H-P, van den Bussche H. Choli‐ nesterase inhibitors for patients with Alzheimer's disease: systematic review of

[99] Salomone S, Caraci F, Leggio GM, Fedotova J, Drago F. New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs. Br J Clin

[100] Caraci F, Bosco P, Leggio GM, Malaguarnera M, Drago F, Bucolo C, et al. Clinical pharmacology of novel anti-Alzheimer disease modifying medications. Curr Top Med

[101] Zetterberg H, Andreasson U, Hansson O, Wu G, Sankaranarayanan S, Andersson ME, et al. Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease. Arch

[102] Hébert SS, Horré K, Nicolaï L, Papadopoulou AS, Mandemakers W, Silahtaroglu AN, et al. Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer's disease correlates with increased BACE1/beta-secretase expression. Proc Natl Acad Sci U S A.

[103] O'Connor T, Sadleir KR, Maus E, Velliquette RA, Zhao J, Cole SL, et al. Phosphorylation of the translation initiation factor eIF2alpha increases BACE1 levels and promotes

[104] Chang W-P, Huang X, Downs D, Cirrito JR, Koelsch G, Holtzman DM, et al. Betasecretase inhibitor GRL-8234 rescues age-related cognitive decline in APP transgenic

[105] Ohno M, Sametsky EA, Younkin LH, Oakley H, Younkin SG, Citron M, et al. BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of

[106] Vassar R. BACE1 inhibitor drugs in clinical trials for Alzheimer's disease. Alzheimers

[107] Henley DB, May PC, Dean RA, Siemers ER. Development of semagacestat (LY450139), a functional gamma-secretase inhibitor, for the treatment of Alzheimer's disease.

[108] Bateman RJ, Siemers ER, Mawuenyega KG, Wen G, Browning KR, Sigurdson WC, et al. A gamma-secretase inhibitor decreases amyloid-beta production in the central

[109] Doody RS, Raman R, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al. A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N Engl J Med. 2013;369(4):

randomised clinical trials. BMJ. 2005;331(7512):321–7.

amyloidogenesis. Neuron. 2008;60(6):988–1009.

Alzheimer's disease. Neuron. 2004;41(1):27–33.

Expert Opin Pharmacother. 2009;10(10):1657–64.

nervous system. Ann Neurol. 2009;66(1):48–54.

mice. FASEB J. 2011;25(2):775–84.

Pharmacol. 2012;73(4):504–17.

162 Update on Dementia

Chem. 2013;13(15):1853–63.

Neurol. 2008;65(8):1102–7.

2008;105(17):6415–20.

Res Ther. 2014;6(9):89.

341–50.


metabolism in patients with Alzheimer's disease. Dement Geriatr Cogn Disord. 2005;19(5–6):256–65.

[135] Sano M, Bell KL, Galasko D, Galvin JE, Thomas RG, van Dyck CH, et al. A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease. Neurology. 2011;77(6):556–63.

[122] Hampel H, Ewers M, Bürger K, Annas P, Mörtberg A, Bogstedt A, et al. Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-

[123] Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Sarmiento J, Troncoso J, Jackson GR, et al. Identification of oligomers at early stages of tau aggregation in

[124] Pritchard SM, Dolan PJ, Vitkus A, Johnson GVW. The toxicity of tau in Alzheimer disease: turnover, targets and potential therapeutics. J Cell Mol Med. 2011;15(8):1621–

[125] Grüninger F. Invited review: drug development for tauopathies. Neuropathol Appl

[126] Collin L, Bohrmann B, Göpfert U, Oroszlan-Szovik K, Ozmen L, Grüninger F. Neuronal uptake of tau/pS422 antibody and reduced progression of tau pathology in a mouse

[127] De Strooper B, Chávez Gutiérrez L. Learning by failing: ideas and concepts to tackle γ-secretases in Alzheimer's disease and beyond. Annu Rev Pharmacol Toxicol.

[128] Fassbender K, Simons M, Bergmann C, Stroick M, Lutjohann D, Keller P, et al. Sim‐ vastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 *in vitro* and *in vivo*. Proc Natl Acad Sci U S A. 2001;98(10):5856–61.

[129] Li L, Cao D, Kim H, Lester R, Fukuchi K-I. Simvastatin enhances learning and memory

[130] Chauhan NB, Siegel GJ, Feinstein DL. Effects of lovastatin and pravastatin on amyloid processing and inflammatory response in TgCRND8 brain. Neurochem Res.

[131] Shepardson NE, Shankar GM, Selkoe DJ. Cholesterol level and statin use in Alzheimer disease: I. Review of epidemiological and preclinical studies. Arch Neurol. 2011;68(10):

[132] Shepardson NE, Shankar GM, Selkoe DJ. Cholesterol level and statin use in Alzheimer disease: II. Review of human trials and recommendations. Arch Neurol. 2011;68(11):

[133] Sjögren M, Gustafsson K, Syversen S, Olsson A, Edman A, Davidsson P, et al. Treatment with simvastatin in patients with Alzheimer's disease lowers both alpha- and betacleaved amyloid precursor protein. Dement Geriatr Cogn Disord. 2003;16(1):25–30.

[134] Hoglund K, Thelen KM, Syversen S, Sjogren M, von Bergmann K, Wallin A, et al. The effect of simvastatin treatment on the amyloid precursor protein and brain cholesterol

independent of amyloid load in mice. Ann Neurol. 2006;60(6):729–39.

model of Alzheimer's disease. Brain. 2014;137(Pt 10):2834–46.

week study. J Clin Psychiatry. 2009;70(6):922–31.

Alzheimer's disease. FASEB J. 2012;26(5):1946–59.

35.

164 Update on Dementia

Neurobiol. 2015;41(1):81–96.

2015;55:419–37.

2004;29(10):1897–911.

1239–44.

1385–92.


[157] Nicolson GL, Ash ME. Lipid replacement therapy: a natural medicine approach to replacing damaged lipids in cellular membranes and organelles and restoring function. Biochim Biophys Acta. 2014;1838(6):1657–79.

[146] Johnson-Anuna LN, Eckert GP, Keller JH, Igbavboa U, Franke C, Fechner T, et al. Chronic administration of statins alters multiple gene expression patterns in mouse

[147] Cole SL, Grudzien A, Manhart IO, Kelly BL, Oakley H, Vassar R. Statins cause intra‐ cellular accumulation of amyloid precursor protein, beta-secretase-cleaved fragments, and amyloid beta-peptide via an isoprenoid-dependent mechanism. J Biol Chem.

[148] Yurko-Mauro K, McCarthy D, Rom D, Nelson EB, Ryan AS, Blackwell A, et al. Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline. Alzheim‐

[149] Freund-Levi Y, Eriksdotter-Jönhagen M, Cederholm T, Basun H, Faxén-Irving G, Garlind A, et al. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Arch Neurol.

[150] Shinto L, Quinn J, Montine T, Dodge HH, Woodward W, Baldauf-Wagner S, et al. A randomized placebo-controlled pilot trial of omega-3 fatty acids and alpha lipoic acid

[151] Jimenez S, Torres M, Vizuete M, Sanchez-Varo R, Sanchez-Mejias E, Trujillo-Estrada L, et al. Age-dependent accumulation of soluble amyloid beta (Abeta) oligomers reverses the neuroprotective effect of soluble amyloid precursor protein-alpha (sAPP(alpha)) by modulating phosphatidylinositol 3-kinase (PI3K)/Akt-GSK-3beta pathway in

[152] Fragkouli A, Papatheodoropoulos C, Georgopoulos S, Stamatakis A, Stylianopoulou F, Tsilibary EC, et al. Enhanced neuronal plasticity and elevated endogenous sAPPα

[153] Thornton E, Vink R, Blumbergs PC, Van Den Heuvel C. Soluble amyloid precursor protein alpha reduces neuronal injury and improves functional outcome following

[154] Lorente-Cebrián S, Costa AGV, Navas-Carretero S, Zabala M, Laiglesia LM, Martínez JA, et al. An update on the role of omega-3 fatty acids on inflammatory and degener‐

[155] Escribá PV. Membrane-lipid therapy: a new approach in molecular medicine. Trends

[156] Escribá PV, Busquets X, Inokuchi J-I, Balogh G, Török Z, Horváth I, et al. Membrane lipid therapy: modulation of the cell membrane composition and structure as a molecular base for drug discovery and new disease treatment. Prog Lipid Res.

levels in mice over-expressing MMP9. J Neurochem. 2012;121(2):239–51.

diffuse traumatic brain injury in rats. Brain Res. 2006;1094(1):38–46.

ative diseases. J Physiol Biochem. 2015;71(2):341–9.

Mol Med. 2006;12(1):34–43.

2015;59:38–53.

cerebral cortex. J Pharmacol Exp Ther. 2005;312(2):786–93.

in Alzheimer's disease. J Alzheimers Dis. 2014;38(1):111–20.

Alzheimer mouse model. J Biol Chem. 2011;286(21):18414–25.

2005;280(19):18755–70.

166 Update on Dementia

2006;63(10):1402–8.

ers Dement. 2010;6(6):456–64.

